Method and nucleic acids for the differentiation of prostate tumors
AssigneeEpigenomics AG
InventorsJuergen Distler, Fabian Model, Peter Adorjan
Life of this patent
Estimating the term…
Abstract
The present invention relates to chemically modified genomic sequences, to oligonucleotides and/or PNA-oligomers for detecting the cytosine methylation state of genomic DNA, as well as to a method for ascertaining genetic and/or epigenetic parameters of genes for use in characterisation, classification, differentiation, diagnosis and therapy of prostate lesions.
Claims32
A method for determining genetic and/or epigenetic parameters for the classification, differentiation and/or diagnosis of prostate tumours or the predisposition to prostate cancer by analysing cytosine methylations, characterised in that the following steps are carried out:
- a. obtaining a biological sample containing genomic DNA
- b. extracting the genomic DNA
- c. in the genomic DNA sample, cytosine bases which are unmethylated at the 5-position are converted, by chemical treatment, to uracil or another base which is dissimilar to cytosine in terms of hybridisation behaviour;
- and
- d. amplifying at least one fragment of the chemically pretreated genomic DNA using sets of primer oligonucleotides and a polymerase,
- wherein the genomic CpG sequences are located within at least one of the chemically pretreated genomic sequences according to Seq. ID No.1 to Seq. ID No.112, and sequences complementary thereto.
An oligomer, in particular an oligonucleotide or peptide nucleic acid (PNA)-oligomer, said oligomer comprising in each case at least one base sequence having a length of at least 9 nucleotides which hybridises to or is identical to a chemically pretreated genomic DNA according to one of the Seq ID Nos 1 to 112.
A nucleic acid comprising a sequence at least 18 bases in length of a segment of the chemically pretreated genomic DNA according to one of the sequences taken from the group of Seq. ID No.1 to Seq. ID No.112 and sequences complementary thereto.
A DNA- and/or PNA-array for analysing prostate cell proliferative disorders, comprising at least one nucleic acid according to one of the preceding claims.
Dependencies are inferred from the claim text.